News
Change of heart as NICE backs prostate cancer drug Talzenna
Thousands of men with prostate cancer will be offered a new treatment, Pfizer's Talzenna, after NICE made an about-turn on the drug.
News
Ovarian cancer data restores faith in Corcept's relacorilant
After Corcept's setback with relacorilant in Cushing syndrome last month, the company has bounced back with strong survival data in ovarian cancer.
News
J&J says 2026 sales could top $100 billion
J&J says its sales should top $100 billion this year, as it pushes its oncology business towards a target of $50 billion by the end of the decade.
News
11 high-impact drugs to look out for in 2026
Medicines for obesity, diabetes, rare diseases, cancer, and women's health feature among Clarivate's annual round-up of 11 Drugs to Watch this year.
Oncology
Astellas’ banner year and focused R&D strategy, with Adam Pe...
At JPM2026, Astellas' chief strategy officer Adam Pearson walked pharmaphorum through the company’s four-pillared R&D strategy.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
